| Literature DB >> 27020673 |
Catharine Chambers1, Danuta M Skowronski, Suzana Sabaiduc, Anne Luise Winter, James A Dickinson, Gaston De Serres, Jonathan B Gubbay, Steven J Drews, Christine Martineau, Alireza Eshaghi, Mel Krajden, Nathalie Bastien, Yan Li.
Abstract
Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network (SPSN) assessed interim 2015/16 vaccine effectiveness (VE) against influenza A(H1N1)pdm09 viruses. Adjusted VE showed significant protection of 64% (95% confidence interval (CI): 44-77%) overall and 56% (95%CI: 26-73%) for adults between 20 and 64 years-old against medically attended, laboratory-confirmed A(H1N1)pdm09 illness. Among the 67 A(H1N1)pdm09-positive specimens that were successfully sequenced, 62 (> 90%) belonged to the emerging genetic 6B.1 subclade, defined by S162N (potential gain of glycosylation) and I216T mutations in the haemagglutinin protein. Findings from the Canadian SPSN indicate that the 2015/16 northern hemisphere vaccine provided significant protection against A(H1N1)pdm09 illness despite genetic evolution in circulating viruses.Entities:
Keywords: effectiveness; influenza; influenza virus; influenza-like illness - ILI; vaccine-preventable diseases; vaccines and immunisation
Mesh：
Substances：
Year: 2016 PMID： 27020673 DOI： 10.2807/1560-7917.ES.2016.21.11.30168
Source DB: PubMed Journal: Euro Surveill ISSN： 1025-496X